|
1
|
Willmer T, Peres J, Mowla S, Abrahams A
and Prince S: The T-Box factor TBX3 is important in S-phase and is
regulated by c-Myc and cyclin A-CDK2. Cell Cycle. 14:3173–3183.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cheng HD, Lui YM and Freimanis RI: A novel
approach to microcalcification detection using fuzzy logic
technique. IEEE Trans Med Imaging. 17:442–450. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
American Cancer Society: Cancer Treatment
and Survivorship Facts and Figures 2012–2013. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/cancer-treatment-and-surviorship-facts-and-figures/cancer-treatment-and-survivorship-facts-and-figures-2012-2013.pdfJanuary
1–2012
|
|
4
|
Ashkenazi A: Targeting the extrinsic
apoptosis pathway in cancer. Cytokine Growth Factor Rev.
19:325–331. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Naiche LA, Harrelson Z, Kelly RG and
Papaioannou VE: T-box genes in vertebrate development. Annu Rev
Genet. 39:219–239. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Peres J and Prince S: The T-box
transcription factor, TBX3, is sufficient to promote melanoma
formation and invasion. Mol Cancer. 12:1172013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bilican B and Goding CR: Cell cycle
regulation of the T-box transcription factor tbx2. Exp Cell Res.
312:2358–2366. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Burgucu D, Guney K, Sahinturk D, Ozbudak
IH, Ozel D, Ozbilim G and Yavuzer U: Tbx3 represses PTEN and is
over-expressed in head and neck squamous cell carcinoma. BMC
Cancer. 12:4812012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Demay F, Bilican B, Rodriguez M, Carreira
S, Pontecorvi M, Ling Y and Goding CR: T-box factors: Targeting to
chromatin and interaction with the histone H3 N-terminal tail.
Pigment Cell Res. 20:279–287. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hoogaars WM, Barnett P, Rodriguez M, Clout
DE, Moorman AF, Goding CR and Christoffels VM: TBX3 and its splice
variant TBX3 + exon 2a are functionally similar. Pigment Cell
Melanoma Res. 21:379–387. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Humtsoe JO, Koya E, Pham E, Aramoto T, Zuo
J, Ishikawa T and Kramer RH: Transcriptional profiling identifies
upregulated genes following induction of epithelial-mesenchymal
transition in squamous carcinoma cells. Exp Cell Res. 318:379–390.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Peres J, Davis E, Mowla S, Bennett DC, Li
JA, Wansleben S and Prince S: The highly homologous T-Box
transcription factors, TBX2 and TBX3, have distinct roles in the
oncogenic process. Genes Cancer. 1:272–282. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hoek K, Rimm DL, Williams KR, Zhao H,
Ariyan S, Lin A, Kluger HM, Berger AJ, Cheng E, Trombetta ES, et
al: Expression profiling reveals novel pathways in the
transformation of melanocytes to melanomas. Cancer Res.
64:5270–5282. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Peres J, Mowla S and Prince S: The T-box
transcription factor, TBX3, is a key substrate of AKT3 in
melanomagenesis. Oncotarget. 6:1821–1833. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Douglas NC and Papaioannou VE: The T-box
transcription factors TBX2 and TBX3 in mammary gland development
and breast cancer. J Mammary Gland Biol Neoplasia. 18:143–147.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wu G, Sinclair C, Hinson S, Ingle JN,
Roche PC and Couch FJ: Structural analysis of the 17q22-23 amplicon
identifies several independent targets of amplification in breast
cancer cell lines and tumors. Cancer Res. 61:4951–4955.
2001.PubMed/NCBI
|
|
17
|
Jacobs JJ, Keblusek P, Robanus-Maandag E,
Kristel P, Lingbeek M, Nederlof PM, van Welsem T, van de Vijver MJ,
Koh EY, Daley GQ, et al: Senescence bypass screen identifies TBX2,
which represses Cdkn2a (p19 (ARF)) and is amplified in a subset of
human breast cancers. Nat Genet. 26:291–299. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Redmond KL, Crawford NT, Farmer H, D'Costa
ZC, O'Brien GJ, Buckley NE, Kennedy RD, Johnston PG, Harkin DP and
Mullan PB: T-box 2 represses NDRG1 through an EGR1-dependent
mechanism to drive the proliferation of breast cancer cells.
Oncogene. 29:3252–3262. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yu J, Ma X, Cheung KF, Li X, Tian L, Wang
S, Wu CW, Wu WK, He M, Wang M, et al: Epigenetic inactivation of
T-box transcription factor 5, a novel tumor suppressor gene, is
associated with colon cancer. Oncogene. 29:6464–6474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wansleben S, Davis E, Peres J and Prince
S: A novel role for the anti-senescence factor TBX2 in DNA repair
and cisplatin resistance. Cell Death Dis. 4:e8462013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yarosh W, Barrientos T, Esmailpour T, Lin
L, Carpenter PM, Osann K, Anton-Culver H and Huang T: TBX3 is
overexpressed in breast cancer and represses p14 ARF by interacting
with histone deacetylases. Cancer Res. 68:693–699. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lomnytska M, Dubrovska A, Hellman U,
Volodko N and Souchelnytskyi S: Increased expression of cSHMT, Tbx3
and utrophin in plasma of ovarian and breast cancer patients. Int J
Cancer. 118:412–421. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Leake R, Barnes D, Pinder S, Ellis I,
Anderson L, Anderson T, Adamson R, Rhodes T, Miller K and Walker R:
Immunohistochemical detection of steroid receptors in breast
cancer: A working protocol. UK Receptor Group, UK NEQAS, The
Scottish Breast Cancer Pathology Group, and The Receptor and
Biomarker Study Group of the EORTC. J Clin Pathol. 53:634–635.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sasaki T, Ryo A, Uemura H, Ishiguro H,
Inayama Y, Yamanaka S, Kubota Y, Nagashima Y, Harada M and Aoki I:
An immunohistochemical scoring system of prolyl isomerase Pin1 for
predicting relapse of prostate carcinoma after radical
prostatectomy. Pathol Res Pract. 202:357–364. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fan W, Huang X, Chen C, Gray J and Huang
T: TBX3 and its isoform TBX3+2a are functionally distinctive in
inhibition of senescence and are overexpressed in a subset of
breast cancer cell lines. Cancer Res. 64:5132–5139. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sasaki K, Bastacky SI, Zynger DL and
Parwani AV: Use of immunohistochemical markers to confirm the
presence of vas deferens in vasectomy specimens. Am J Clin Pathol.
132:893–898. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li X, Gao H, Chen Z, Zhang L, Zhu X, Wang
S and Peng W: Diagnosis of breast cancer based on
microcalcifications using grating-based phase contrast CT. Eur
Radiol. 28:3742–3750. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wu SG, He ZY, Zhou J, Sun JY, Li FY, Lin
Q, Guo L and Lin HX: Serum levels of CEA and CA15-3 in different
molecular subtypes and prognostic value in Chinese breast cancer.
Breast. 23:88–93. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Di Gioia D, Blankenburg I, Nagel D,
Heinemann V and Stieber P: Tumor markers in the early detection of
tumor recurrence in breast cancer patients: CA 125, CYFRA 21-1,
HER2 shed antigen, LDH and CRP in combination with CEA and CA 15-3.
Clin Chim Acta. 461:1–7. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang W, Xu X, Tian B, Wang Y, Du L, Sun T,
Shi Y, Zhao X and Jing J: The diagnostic value of serum tumor
markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast
cancer. Clin Chim Acta. 470:51–55. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Willmer T, Hare S, Peres J and Prince S:
The T-box transcription factor TBX3 drives proliferation by direct
repression of the p21(WAF1) cyclin-dependent kinase inhibitor. Cell
Div. 11:62016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Horton AC, Mahadevan NR, Minguillon C,
Osoegawa K, Rokhsar DS, Ruvinsky I, de Jong PJ, Logan MP and
Gibson-Brown JJ: Conservation of linkage and evolution of
developmental function within the Tbx2/3/4/5 subfamily of T-box
genes: Implications for the origin of vertebrate limbs. Dev Genes
Evol. 218:613–628. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Aran D, Camarda R, Odegaard J, Paik H,
Oskotsky B, Krings G, Goga A, Sirota M and Butte AJ: Comprehensive
analysis of normal adjacent to tumor transcriptomes. Nat Commun.
8:10772017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kunasegaran K, Ho V, Chang TH, De Silva D,
Bakker ML, Christoffels VM and Pietersen AM: Transcriptional
repressor Tbx3 is required for the hormone-sensing cell lineage in
mammary epithelium. PLoS One. 9:e1101912014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sunwoo HH and Suresh MR: Cancer markers.
In The ImmunoassayHandbook. 1. 4th edition. Elsevier Ltd.; Oxford:
pp. 673–693. 2013
|
|
36
|
Willmer T, Cooper A, Peres J, Omar R and
Prince S: The T-Box transcription factor 3 in development and
cancer. Biosci Trends. 11:254–266. 2017. View Article : Google Scholar : PubMed/NCBI
|
